Assessing the Financial Impact of Translational Pharmaceutics - A Platform for Accelerating Drug Development
We are dedicated to accelerating the development of new drugs for patients around the world. We provide CRO and CDMO services including formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry. These services are provided either individually or as an integrated service offering via our Translational Pharmaceutics® platform.
Quotient is your answer.
Quotient is your answer.
Quotient is your answer.
Quotient is your answer.
Quotient is your answer.
Our latest updates
News
Tufts Center for the Study of Drug Development (CSDD) today published a white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms.
Exhibition
Schedule a partnering meeting at Biotech Showcase with our CSO, Peter Scholes and Senior Director of Business Development, Katie Stuart to share your drug development needs.
Case Studies
Druggability Technologies (DRGT) is developing DRGT-46 as a novel therapy for pain. Gabor Heltovics, CEO of DRGT, explains how Quotient Sciences enabled the rapid development, clinical assessment and commercial readiness of its DRGT- 46 product using integrated services across Quotient’s network of harmonized development and manufacturing sites in the UK and US.
Scientific Posters
HBI-3000 (sulcardine sulfate trihydrate; Bai, et al. 2012) is a multi-ion channel blocker with effects on INa-Peak, INa-Late, ICa,L, and IKr with similar in vitro potencies across these various ion channels in human atrial cardiomyocytes. It is being eveloped by HUYA Bioscience International® (HUYABIO™) for the conversion of recent onset atrial fibrillation (AF).
Ask us a question
